Analysis Hello,
I have been looking into this company and its potential upside. There are numerous positive aspects such as successful trials, increased dosage study and $5B annual sales market for AKI. The science and studies are impresdive to say the least. The company has received funding from various Canadian government agencies which inusual but adds comfort in my opinion. The company has added a couple of strategic advisers with big pharma connections.
The negatives I see are the company is Canadian and on a risky exchange with a lot of negative history attached to it. The company recently gained analyst coverage from Raymond James and although the analysts provided cautious optimism they had concerns on the lack of data provided on their last trial. The independent data analysis generally takes about 6 months at the conclusion of the trial and I believe the study was Feb 2022 so long over due.
The company has a $135M market cap which seems extremely low for a similar staged company. There is very little communication from the company and the share price has been on a steady devline for a year now and continues to hit new 52 week lows.
Is anyone aware of when the next trial will be started and if or when the company will provide data that the Raymond James analysts and markets are waiting for. My concern hear is trying to catch a falling knife and I feel the share price could go lower. It appears that management are not proactive in communicating to the markets. I am not looking for fluff but actual data that supports the science and de-risks the potential for approval.
My concern here is that even the dole analyst has concerns yet management has failed to address their concerns.